undamentalytics Newsletter
Sign in

ASP Isotopes Inc. (ASPI) stock

Add to watchlist

Add holding +

NASDAQ: ASPI Nasdaq Specialty Chemicals Next results ~November 12, 2026

C Fundamentals grade

ASP Isotopes Inc. is a US-listed company in the specialty chemicals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for ASP Isotopes Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

ASP Isotopes Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 7 selling2 purchases and 30 sales by directors and officers, last 12 monthsInsider trades
  • Funds111 adding, 79 cuttingOf 28 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter ASP Isotopes files

Where ASP Isotopes stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $31m, up 573.4% on a year earlier, faster than the 511.2% growth a quarter earlier. That growth ranks 1 of 35 among the specialty chemicals companies we cover. Free-cash-flow margin rose to -270.9% from -645.8% a year earlier. Operating margin widened to -321.1% from -720.4%. The diluted share count is up 59.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 4 of our 6 financial-health checks.

Our model value for ASP Isotopes is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

ASP Isotopes Inc.'s trailing-twelve-month revenue grew 573.4% year on year, with a free-cash-flow margin of -270.9%. Where it stands out: revenue growth of 573.4% ranks 1 of 42 specialty chemicals companies we cover. Where it lags: net margin of -380.3% ranks 39 of 42 specialty chemicals companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 573.4% (+62.2pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 573.4% over the last 12 months, against a median of 6.0% for specialty chemicals companies we cover.
  • Growth speeding up. The growth rate is 62.2 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 399.3 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Loss-making. Operating margin is -321.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -270.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 60.5% of revenue, against a median of 1.0% for specialty chemicals companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 59.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 99% and a beta of 3.9 against the S&P 500.
  • Gross margin slipping. Gross margin is down 20.9 points on a year ago.

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$0.25 against an average estimate of -$0.31: beat by 18.5%
Revenue
$5m, up 327.6% on a year earlier
Share reaction
-2.2% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Guidance given
PET Labs revenue $14m (FY 2026); renergen annualized helium and LNG revenue $27m (after the expected completion of Phase 1)
Next report
November 12, 2026; average EPS estimate -$0.13

ASP Isotopes' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.0%
  • 1 week-4.0%
  • 1 month-33.3%
  • This year-63.7%
  • 1 year-80.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$30.9M
Operating margin
-321.1%
Net margin
-380.3%
EPS (TTM, diluted)
$-1.08

Growth

Revenue growth
+573.4%
Change in growth rate
+62.2 pts
Share count change
+59.6%

Cash

Free cash flow (TTM)
-$83.6M
FCF margin
-270.9%
Stock pay % of revenue
60.5%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Agreement
  6. Announcement
  7. Announcement
  8. Announcement
  9. Announcement
  10. Results
  11. Guidance
  12. Announcement
  13. Announcement
  14. Announcement
  15. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

ASP Isotopes Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value ASP Isotopes Inc. as an operating company, with every model that fits that kind of business. Cost of equity 12.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.63 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.1 ~$0.2–$0.6 Left out: out of range vs price (0.06x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare ASP Isotopes Inc. with Specialty Chemicals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$1.58$1.79$4.53$5.35$1.94
Market value$42m$59m$252m$444m$210m
+ Net debt (− = net cash)−$2m−$7m−$27m−$80m$38m
Enterprise value$40m$52m$226m$364m$248m
Multiples
Price / sales —136.7x60.9x18.6x6.8x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $5m and EPS of −$0.13 (range −$0.13 to −$0.13) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.70 +67% $20m −16%
Next −$0.83 — $58m +190%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −51.2% on 90 days ago. In the last 30 days, 1 analyst raised ASP Isotopes Inc.'s forecast and 1 cut it.

Consensus EPS forecast ASP Isotopes Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.44 Current fiscal year, 60 days ago: −$1.44 Current fiscal year, 30 days ago: −$0.56 Current fiscal year, 7 days ago: −$0.65 Current fiscal year, Now: −$0.70 −$0.70 Next fiscal year, 90 days ago: −$1.16 Next fiscal year, 60 days ago: −$1.16 Next fiscal year, 30 days ago: −$1.16 Next fiscal year, 7 days ago: −$0.71 Next fiscal year, Now: −$0.83 −$0.83

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.44−$1.16
60 days ago −$1.44−$1.16
30 days ago −$0.56−$1.16
7 days ago −$0.65−$0.71
Now −$0.70−$0.83

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.31 −$0.25 +18.5%
Mar 2026 −$0.28 −$0.05 +82.1%
Dec 2025 −$0.14 −$0.41 −200.0%
Sept 2025 −$0.10 −$0.15 −50.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026
  • PET Labs revenue FY 2026 about $14m
    “We forecast that PET Labs is on track to deliver FY 2026 revenues of approximately $14 million, up from $6 million in 2025.” source
  • Renergen annualized helium and LNG revenue after the expected completion of Phase 1 about $27m
    “At current expected prices, annualized forecasted helium and LNG revenues are expected to be approximately $27 million after the expected completion of Phase 1.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202633
  2. Sep 202633

Counts of recommendations published by analysts covering ASP Isotopes Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
20.7%
of tradable shares
Days to cover
5.78
at average volume
Short interest, 1 month
+11%
to October 15, 2026
Held by institutions
47%
of shares
Held by insiders
10.5%
of shares
Employees
271
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
ASPI+13%+153%+18%−64%
Industry peers (median)−9%+6%−15%+6%
S&P 500+26%+25%+18%+11%
Months that ended higher
ASPI50%50%58%36%
S&P 50067%75%75%46%
Largest fall from a high during the year
ASPI−84%−63%−62%−77%
S&P 500−10%−8%−19%−9%

Worst fall since November 10, 2022: 89% from November 11, 2022 to May 17, 2023. Getting back needed a 775% gain, reached on February 1, 2024, 260 days after the low.

Price behaviour

52-week range
$1.94 – $9.15
From 52-week high
−78.8%
vs 50-day average
−33.9%
vs 200-day average
−59.8%
Volatility (1 year)
99%
Beta vs S&P 500
3.88

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
0 up, 1 down
typical move ±2.2%
After a week
1 up, 0 down
typical move ±4.3%
After a month
0 up, 1 down
typical move ±5.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 −2.2% +1.6% +4.3% −5.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

ASP Isotopes Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) ASP Isotopes Inc.
$0 $10M $20M $30M $40M FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY23 Q4: $433K Revenue (TTM), FY24 Q1: $1.3M Revenue (TTM), FY24 Q2: $2.3M Revenue (TTM), FY24 Q3: $3.4M Revenue (TTM), FY24 Q4: $4.1M Revenue (TTM), FY25 Q1: $4.4M Revenue (TTM), FY25 Q2: $4.6M Revenue (TTM), FY25 Q3: $8.4M Revenue (TTM), FY25 Q4: $23.8M Revenue (TTM), FY26 Q1: $26.9M Revenue (TTM), FY26 Q2: $30.9M $30.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $433K
FY24 Q1 $1.3M
FY24 Q2 $2.3M
FY24 Q3 $3.4M
FY24 Q4 $4.1M
FY25 Q1 $4.4M
FY25 Q2 $4.6M
FY25 Q3 $8.4M
FY25 Q4 $23.8M
FY26 Q1 $26.9M
FY26 Q2 $30.9M
Revenue growth, TTM YoY ASP Isotopes Inc.
0% 500% 1000% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY24 Q4: 857.0% Revenue growth, TTM YoY, FY25 Q1: 246.0% Revenue growth, TTM YoY, FY25 Q2: 99.6% Revenue growth, TTM YoY, FY25 Q3: 147.8% Revenue growth, TTM YoY, FY25 Q4: 475.5% Revenue growth, TTM YoY, FY26 Q1: 511.2% Revenue growth, TTM YoY, FY26 Q2: 573.4% 573.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q4 857.0%
FY25 Q1 246.0%
FY25 Q2 99.6%
FY25 Q3 147.8%
FY25 Q4 475.5%
FY26 Q1 511.2%
FY26 Q2 573.4%
Operating margin (TTM) ASP Isotopes Inc.
-4000% -3000% -2000% -1000% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY23 Q4: -3704.6% Operating margin (TTM), FY24 Q1: -1423.9% Operating margin (TTM), FY24 Q2: -925.3% Operating margin (TTM), FY24 Q3: -671.8% Operating margin (TTM), FY24 Q4: -636.0% Operating margin (TTM), FY25 Q1: -646.7% Operating margin (TTM), FY25 Q2: -720.4% Operating margin (TTM), FY25 Q3: -507.4% Operating margin (TTM), FY25 Q4: -251.2% Operating margin (TTM), FY26 Q1: -285.4% Operating margin (TTM), FY26 Q2: -321.1% -321.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -3704.6%
FY24 Q1 -1423.9%
FY24 Q2 -925.3%
FY24 Q3 -671.8%
FY24 Q4 -636.0%
FY25 Q1 -646.7%
FY25 Q2 -720.4%
FY25 Q3 -507.4%
FY25 Q4 -251.2%
FY26 Q1 -285.4%
FY26 Q2 -321.1%
FCF margin (TTM) ASP Isotopes Inc.
-2000% -1500% -1000% -500% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY23 Q4: -1788.3% FCF margin (TTM), FY24 Q1: -797.3% FCF margin (TTM), FY24 Q2: -718.6% FCF margin (TTM), FY24 Q3: -723.7% FCF margin (TTM), FY24 Q4: -636.4% FCF margin (TTM), FY25 Q1: -627.2% FCF margin (TTM), FY25 Q2: -645.8% FCF margin (TTM), FY25 Q3: -384.9% FCF margin (TTM), FY25 Q4: -198.9% FCF margin (TTM), FY26 Q1: -244.6% FCF margin (TTM), FY26 Q2: -270.9% -270.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -1788.3%
FY24 Q1 -797.3%
FY24 Q2 -718.6%
FY24 Q3 -723.7%
FY24 Q4 -636.4%
FY25 Q1 -627.2%
FY25 Q2 -645.8%
FY25 Q3 -384.9%
FY25 Q4 -198.9%
FY26 Q1 -244.6%
FY26 Q2 -270.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 4 24 31
Gross profit 0 0 2 3 6
EBITDA −5 −16 −26 −58 −94
Operating income −5 −16 −26 −60 −99
Net income −5 −16 −32 −160 −117
Diluted EPS — −$0.49 −$0.63 −$2.11 −$1.08
Growth (year on year)
Revenue — — +857.0% +475.5% +573.4%
Margins
Gross margin — 32.1% 38.6% 14.3% 18.3%
EBITDA margin — <−999% −624.6% −243.2% −303.3%
Operating margin — <−999% −636.0% −251.2% −321.1%
Net margin — <−999% −782.4% −670.2% −380.3%
Free-cash-flow margin — <−999% −636.4% −198.9% −270.9%
Cash flow
Cash from operations −3 −5 −17 −38 −68
Capital spending 4 2 10 10 16
Free cash flow −7 −8 −26 −47 −84
Stock-based pay 2 9 9 16 19
Free cash flow after stock pay −9 −16 −35 −63 −102
Balance sheet
Cash 2 8 62 280 220
Total debt 0 0 35 200 258
Net debt (negative = net cash) −2 −7 −27 −80 38
Diluted shares 27m 33m 56m 83m 108m
Returned to shareholders
Dividends — 0 3 0 —
Total returned — 0 3 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $572m
Short-term assets $272mLonger-term assets $300m
What it owes, and who funded it · $562m
Short-term liabilities $70mLonger-term liabilities $227mShareholders' equity $265m
  • Short-term assets cover short-term liabilities $272m of assets due within a year against $70m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $272m short-term assets against $227m of longer-dated liabilities.
  • More cash than debt $220m of cash against $60m of debt.
  • Debt below 40% of shareholders' equity Debt is 23% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$68m of operating cash flow against $60m of debt.
  • Operating profit covers interest at least five times over Operating income of −$99m against $4m of interest.

From ASP Isotopes Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+59.6%
year over year
R&D spending
71.4%
of revenue

Competitors: side by side with peers

Closest by revenue in specialty chemicals
Last 12 months unless stated ASPI CNEY TANH BON PMA NTIC Median
Revenue, last 12 months $31m $36m $38m $19m $15m $92m $906m
Revenue growth, last 12 months 573.4% −30.2% −10.7% −21.7% −56.8% 7.7% 5.4%
Revenue growth, 3-year average — — −14.4% — — 5.0% 0.9%
Revenue growth, latest quarter 327.6% — — — — 12.6% 8.3%
Gross margin 18.3% 1.8% 18.6% 20.8% −18.4% 35.8% 28.8%
Operating margin −321.1% −30.9% −31.8% −8.7% −37.4% 3.0% 4.3%
Operating margin, 3-year average −655.6% — −12.1% — — 5.8% 5.5%
Net margin −380.3% −31.3% −80.9% −10.7% −39.4% −1.3% 0.8%
Cash from operations / revenue −219.8% −5.5% −15.2% 0.8% 5.4% −2.3% 6.9%
Free-cash-flow margin −270.9% −5.5% −15.2% 0.7% 4.8% −3.5% 4.3%
Free-cash-flow margin, 3-year average −545.1% — −9.4% — — 1.9% 5.1%
Stock pay / revenue 60.5% — 0.0% 7.5% — 1.4% 1.0%
Change in share count 59.6% 610.5% 444.4% >999% 9.5% −2.4% 0.1%

Median of all 42 companies we cover in specialty chemicals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

42 specialty chemicals companies
Measure Company Peer median Rank
Revenue growth Growth 573.4% 6.0% 1 of 42
Change in growth rate Growth +62.2pp +1.3pp 1 of 42
Gross margin Profitability 18.3% 31.5% 32 of 40
Operating margin Profitability -321.1% 3.8% 35 of 39
Net margin Profitability -380.3% 1.7% 39 of 42
Free-cash-flow margin Cash generation -270.9% 4.8% 39 of 42
Stock pay as % of revenue Cash generation 60.5% 1.0% 33 of 36
Long-term debt as % of assets Balance sheet 0.9% 26.8% 4 of 36
Change in share count Balance sheet 59.6% 0.0% 34 of 37

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Construction $18.2M 76.2% —
Products $5.7M 23.8% ▲ 43.9%
Collaboration Revenue $0 0.0% ▼ 100.0%
Geography
Region Revenue Share YoY
Hong Kong $18.2M 76.2% —
ZA $4.8M 20.2% ▲ 16.4%
United States $852,000 3.6% —

From ASP Isotopes Inc.'s 10-K filed April 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$406M
Institutions reporting
185
Shares held vs prior quarter
▲ 1.9%
Positions opened / closed
37 / 28

Top buyers and sellers, Q2 2026: 111 institutions bought and 79 sold ; the biggest buyer was Blackrock, Inc (+889K shares) and the biggest seller Jane Street Group, LLC (−663K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $57.3M 9.2M 14.1% ▲ 10.7%
Encompass Capital Advisors LLC $40.8M 6.6M 10.0% ▼ 5.1%
Vanguard Capital Management LLC $31M 5.0M 7.6% ▼ 1.5%
Rovida Investment Management Ltd $25.5M 4.1M 6.3% 0.0%
UBS Group AG $20.2M 3.2M 5.0% ▲ 14.3%
Geode Capital Management, LLC $18.3M 2.9M 4.5% ▲ 7.5%
Alyeska Investment Group, L.P. $17.7M 2.8M 4.4% ▲ 5.6%
State Street Corp $16.1M 2.6M 4.0% ▲ 11.8%
Exchange Traded Concepts, LLC $14M 2.3M 3.5% ▲ 3.3%
Awm Investment Company, Inc. $9.8M 1.6M 2.4% ▼ 25.6%
BNP Paribas Asset Management Holding S.A. $9.8M 1.6M 2.4% ▲ 77.7%
Philadelphia Financial Management Of San Francisco, LLC $8.4M 1.3M 2.1% ▲ 107.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not ASP Isotopes Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $61,800 2 trades by 1 insider, last 12 months Insider sales History → $9.5M 30 trades by 7 insiders · 79% under pre-set plans
Net ▼ $9.5M net selling
Insider Date Trade Shares Price Value
Kiessling Heather Chief Financial Officer October 16, 2026 Sell 21,830 $2.19 $47,808
Ainscow Robert COO October 14, 2026 Sell pre-set plan 22,500 $2.11 $47,565
Ryan Robert John Andrew Director September 30, 2026 Buy 15,000 $2.68 $40,200
Ryan Robert John Andrew Director September 28, 2026 Buy 8,000 $2.70 $21,600
Ainscow Robert COO September 8, 2026 Sell pre-set plan 8,438 $4.29 $36,199
Mann Paul Elliot Chairman and CEO September 4, 2026 Sell pre-set plan 83,759 $4.10 $343,412
Mann Paul Elliot Chairman and CEO September 3, 2026 Sell pre-set plan 83,758 $3.92 $328,331
Mann Paul Elliot Chairman and CEO September 2, 2026 Sell pre-set plan 83,758 $3.91 $327,494
Ainscow Robert COO September 2, 2026 Sell pre-set plan 25,000 $3.91 $97,750
Ainscow Donald George EVP, Gen Counsel, Secretary September 2, 2026 Sell 23,678 $3.89 $92,107
Kiessling Heather Chief Financial Officer July 1, 2026 Sell pre-set plan 23,124 $6.28 $145,219
Gorley Michael Director June 30, 2026 Sell 30,000 $6.27 $188,100

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 4, 2026

Recent SEC filings

Data status

When each part of this page on ASP Isotopes Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

ASP Isotopes Inc. in brief

What does ASP Isotopes Inc. do?
ASP Isotopes Inc. is a US-listed company in the specialty chemicals industry. Its financial year ends in December.
What is ASP Isotopes Inc.'s stock ticker?
ASP Isotopes Inc. trades under the ticker ASPI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is ASP Isotopes Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, ASP Isotopes Inc. reported revenue of $30.9M, 573.4% higher than a year earlier, according to its SEC filings.
What is ASP Isotopes Inc.'s free cash flow?
ASP Isotopes Inc.'s free-cash-flow margin is -270.9% of revenue over the trailing twelve months, ranking 39 of the 42 specialty chemicals companies we cover.
Who are ASP Isotopes Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Encompass Capital Advisors LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is ASP Isotopes Inc.'s market cap?
On November 2, 2026, ASP Isotopes Inc.'s market capitalisation was about $210M and net debt of $38.3M. Market figures come from third-party market data and may be delayed.
How much debt does ASP Isotopes Inc. have?
ASP Isotopes Inc.'s debt-to-equity ratio is 22.6%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are ASP Isotopes Inc.'s competitors?
In our Specialty Chemicals peer group, the companies closest to ASP Isotopes Inc. are CN Energy Group. Inc., Tantech Holdings LTD, Bon Natural Life Ltd, PMA Graphene Technology Group Inc. and Northern Technologies International Corp. The side-by-side comparison below sets their revenue, margins and growth against ASP Isotopes Inc.'s.
Are insiders buying or selling ASP Isotopes Inc. stock?
Over the last 12 months, ASP Isotopes Inc.'s directors and officers reported 2 open-market purchases and 30 sales on Form 4. The insider trading page charts every trade.
When is ASP Isotopes Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — ASP Isotopes Inc. announces its own schedule.